Lin Jieheng, Yang Jianying, Wang Wenping, Lin Xiaotong, Cao Yang
Department of Oncology Center, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Front Oncol. 2021 Dec 22;11:775147. doi: 10.3389/fonc.2021.775147. eCollection 2021.
We report a rare case of PDL1-negative advanced gastric adenocarcinoma that improved significantly after camrelizumab plus chemotherapy followed by camrelizumab plus capecitabine as first-line therapy. A 65-year-old woman was diagnosed with a gastric adenocarcinoma in 2017 contrast-enhanced computed tomography (CT) and endoscopic biopsy. She stabilised after preoperative neoadjuvant chemotherapy, surgery, and postoperative adjuvant chemotherapy. In September 2019, positron emission tomography (PET)/CT re-examination suggested a peritoneal metastasis and multiple lymph node metastases. She then received six cycles of camrelizumab plus chemotherapy. PET/CT indicated that the metastatic foci had disappeared and that she had achieved a clinical complete response(CCR). She was followed-up with camrelizumab plus capecitabine (maintenance therapy). At the time of writing, her progression-free survival is more than 14 months and her quality of life is good. Thus, camrelizumab plus chemotherapy is a useful first-line treatment for HER2- and PD-L1-negative advanced gastric adenocarcinoma.
我们报告了一例罕见的PDL1阴性晚期胃腺癌病例，该患者在接受卡瑞利珠单抗联合化疗，随后使用卡瑞利珠单抗联合卡培他滨作为一线治疗后有显著改善。一名65岁女性在2017年经增强计算机断层扫描（CT）和内镜活检被诊断为胃腺癌。她在术前新辅助化疗、手术及术后辅助化疗后病情稳定。2019年9月，正电子发射断层扫描（PET）/CT复查提示腹膜转移和多发淋巴结转移。随后她接受了六个周期的卡瑞利珠单抗联合化疗。PET/CT显示转移灶消失，达到临床完全缓解（CCR）。她接受卡瑞利珠单抗联合卡培他滨进行随访（维持治疗）。在撰写本文时，她的无进展生存期超过14个月，生活质量良好。因此，卡瑞利珠单抗联合化疗是HER2和PD - L1阴性晚期胃腺癌的一种有效一线治疗方法。
